Patents by Inventor Núria Gavaldà Batalla

Núria Gavaldà Batalla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapy for transthyretin-associated amyloidosis
    Patent number: 11564899
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: January 31, 2023
    Assignee: SOM Innovation Biotech, S.L.
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
  • Therapy for Transthyretin-Associated Amyloidosis
    Publication number: 20200390733
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Application
    Filed: August 28, 2020
    Publication date: December 17, 2020
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
  • Therapy for transthyretin-associated amyloidosis
    Patent number: 10786473
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: September 29, 2020
    Assignee: SOM Innovation Biotech, S.L.
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
  • New Therapy for Transthyretin-Associated Amyloidosis
    Publication number: 20200138760
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Application
    Filed: September 12, 2019
    Publication date: May 7, 2020
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
  • Therapy for transthyretin-associated amyloidosis
    Patent number: 10449169
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: October 22, 2019
    Assignee: SOM Innovation Biotech, S.L.
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Núria Reig Bolano, Nuria Gavaldà Batalla
  • Therapy for Transthyretin-Associated Amyloidosis
    Publication number: 20190091188
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Application
    Filed: August 13, 2018
    Publication date: March 28, 2019
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Núria Reig Bolano, Nuria Gavaldà Batalla
  • Therapy for transthyretin-associated amyloidosis
    Patent number: 10045956
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 14, 2018
    Assignee: SOM Innovation Biotech, S.L.
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Núria Reig Bolano, Nuria Gavaldà Batalla
  • THERAPEUTIC AGENTS FOR USE IN THE PROPYLAXIS AND/OR TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS
    Publication number: 20180042869
    Abstract: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.
    Type: Application
    Filed: September 22, 2017
    Publication date: February 15, 2018
    Inventors: Nuria GAVALDA BATALLA, Raul INSA BORONAT, Nuria REIG BOLANO
  • New Therapy for Transthyretin-Associated Amyloidosis
    Publication number: 20170304243
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Application
    Filed: March 2, 2017
    Publication date: October 26, 2017
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolano, Núria Gavaldà Batalla
  • Therapeutic agents for use in the propylaxis and/or treatment of hyperkinetic movement disorders
    Patent number: 9789072
    Abstract: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: October 17, 2017
    Assignee: SOM INNOVATION BIOTECH, S.L.
    Inventors: Nuria Gavalda Batalla, Raul Insa Boronat, Nuria Reig Bolano
  • Therapy for transthyretin-associated amyloidosis
    Patent number: 9610270
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: April 4, 2017
    Assignee: SOM INNOVATION BIOTECH, S.L.
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
  • THERAPEUTIC AGENTS FOR USE IN THE PROPYLAXIS AND/OR TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS
    Publication number: 20160158167
    Abstract: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyllamine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.
    Type: Application
    Filed: June 18, 2014
    Publication date: June 9, 2016
    Inventors: Nuria GAVALDA BATALLA, Raul INSA BORONAT, Nuria REIG BOLANO
  • NEW THERAPY FOR TRANSTHYRETIN-ASSOCIATED AMYLOIDOSIS
    Publication number: 20140296188
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Application
    Filed: October 23, 2012
    Publication date: October 2, 2014
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla